Group 1: Financial Performance - As of December 31, 2023, the company's accounts receivable balance was 1,606.40 million CNY, with a bad debt provision of 234.78 million CNY, resulting in a bad debt provision rate of 14.62% [2][4] - The bad debt provision policy is based on the aging of accounts receivable, with rates of 5% for under 1 year, 10% for 1-2 years, 20% for 2-3 years, 50% for 3-4 years, 80% for 4-5 years, and 100% for over 5 years [4] Group 2: Revenue Recognition and Project Management - The company employs a completed contract method for revenue recognition in its medical purification system integration projects [4] - As of March 31, 2024, the company had an order backlog of 2,686 million CNY and revenue of 229 million CNY [4] Group 3: Accounts Receivable Management - The company conducts regular assessments of customer creditworthiness and strengthens collection efforts for overdue payments [4] - Accounts receivable collection rates and amounts are key performance indicators for the business and sales departments [4] Group 4: Project Progress and Future Outlook - Two ongoing projects have commenced as scheduled, with no anticipated delays due to the postponement of convertible bond issuance [5]
华康医疗(301235) - 2024年5月16日投资者关系活动记录表